6.5 months 0.5-1.5mg d/Dut and 5-10mg OM. Have I regressed?
    Progress Pictures 5/28/2025

    From the encyclopedia
    Dutasteride →

    Heavy duty finasteride that comes with higher risks

    Finasteride →

    Frontline, gold standard treatment for combatting androgenic alopecia

    RU58841 →

    a potent but unapproved and potentially problematic topical anti-androgen

    At a glance
    In this treatment experience post, the primary subjects mentioned are
    💊 Dutasteride (oral) 0.5-2.5mg daily 6.5 months
    💊 Oral Minoxidil (oral) 5-10mg daily 6.5 months
    💊 Finasteride (oral) 1.25mg daily 13.5 months
    💧 RU58841 (topical) 50mg daily 2 weeks
    💧 Dermarolling (topical) occasionally 13.5 months
    💧 Topical Minoxidil (topical) 1x daily 3-4 months
    the tone is 😞 negative.

    Other terms

    The user has been using various hair loss treatments, including dutasteride, oral minoxidil, finasteride, RU58841, and dermarolling, but feels they may have lost hair and is considering a hair transplant. They are advised to stick to one treatment for 6-12 months to see results, as frequent changes may hinder progress.
    View this post in the Community →

    Similar Community Posts Join

    6 / 6 results

    Related Research

    6 / 6 results
      Experimental and Early Investigational Drugs for Androgenetic Alopecia

      research Experimental and early investigational drugs for androgenetic alopecia

      11 citations , July 2017 in “Expert Opinion on Investigational Drugs”
      This review discusses current and emerging therapeutic strategies for androgenetic alopecia, noting limited evidence but suggesting areas such as prostaglandin analogs, PRP, and progenitor cell therapies as promising future directions.
      Clinical Updates in Hair

      research CLINICAL UPDATES IN HAIR

      19 citations , January 1997 in “Dermatologic Clinics”
      This chapter reviews various antiandrogens and androgen inhibitors, detailing their mechanisms, uses, and side effects, with a focus on spironolactone, finasteride, dutasteride, and oral contraceptives.
      Antiandrogens and Androgen Inhibitors in Dermatologic Treatments

      research Antiandrogens and Androgen Inhibitors

      November 2020 in “Elsevier eBooks”
      This source outlines various antiandrogen and androgen inhibitor drugs used to treat cutaneous disorders of hyperandrogenism, detailing their mechanisms, uses, dosages, and side effects, with emphasis on spironolactone, finasteride, dutasteride, and oral contraceptives.
      The Modern Treatment of Androgenetic Alopecia

      research Тіе Modern treatment of androgenetic alopecia

      February 2017 in “Vestnik dermatologii i venerologii”
      This review examines the molecular mechanisms and current treatment options for androgenetic alopecia, highlighting potential future therapies but providing no new experimental findings.
      New Therapeutics in the Management of Androgenetic Alopecia

      research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique

      March 2025 in “HAL (Le Centre pour la Communication Scientifique Directe)”
      This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.